Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Gilead bolsters cancer portfolio with $21 bln acquisition of Immunomedics

share with twitter share with LinkedIn share with facebook
09/14/2020 | 05:38am EDT

* Gilead gains prized antibody-drug-conjugate

* Trodelvy targets elusive and aggressive type of breast cancer

* Bid is 108% above last closing price

Sept 14 (Reuters) - Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.

The deal will give Gilead access to Immunomedics' breast cancer treatment drug Trodelvy, which was granted an accelerated FDA approval in April for an aggressive and tough to treat type of breast cancer.

Gilead said it would issue a tender offer to buy all the outstanding shares of Immunomedics for $88 per share, representing a premium of about 108% over their last closing price of $42.25 on Friday.

"This acquisition represents significant progress in Gilead's work to build a strong and diverse oncology portfolio," Gilead Chief Executive Officer Daniel O'Day said in a statement. "Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer."

Immunomedics is also on track to file for regulatory approval for Trodelvy in Europe in the first half of 2021, according to the statement.

The deal - and a separate transaction between Merck & Co and Seattle Genetics's announced on Monday - was a sign of renewed confidence in an approach in oncology to pair antibodies with toxic agents to fight cancer.

Immunomedics' Trodelvy is a so-called antibody-drug conjugates, or ADC, a class described by researchers as "guided missiles" that zero in on tumors to release cytotoxins that deliver up to 10,000 times the potency of standard chemotherapy, while minimizing damage to healthy tissue.

Merck, for its part, struck a deal with Seattle Genetics worth up to $4.2 billion, comprising stock purchases, an upfront payment and milestone rewards, to collaborate with the partner on two ADCs against breast cancer and other tumors.

In previous landmark deals for the field, AstraZeneca last year committed up to $7 billion for rights to Daiichi Sankyo's Enhertu, another breast-cancer targeted ADC. It followed up in July with a deal worth up to $6 billion for DS-1062, another ADC developed by the Japanese drugmaker.

Trodelvy targets triple-negative breast cancer that has spread to other organs. Both aggressive and tough to treat, those tumor types account for 15-20% of breast cancers, lacking three genetic characteristics for which there are more treatment options.

Cancer immunotherapy Tecentriq by Gilead CEO O'Day's former employer Roche has emerged as a new treatment option for this patient group.

Gilead's offer will be funded with $15 billion in cash on hand, and through $6 billion in newly issued debt, according to the drugmaker.

The transaction is expected to close in the fourth quarter of 2020, the companies said.

The acquisition of Immunomedics is the latest of the several Gilead inked this year with the aim of expanding its oncology portfolio.

It bought a 49.9% stake in cancer drug developer Pionyr Immunotherapeutics in June for $275 million, just months after paying $4.9 billion for Forty Seven Inc, maker of an experimental treatment that targets blood cancer.

(Reporting by Ann Maria Shibu in Bengaluru and Ludwig Burger in Frankfurt; Editing by Peter Cooney, Diane Craft and Susan Fenton)


Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.15% 7943 Delayed Quote.4.42%
DAIICHI SANKYO COMPANY, LIMITED -0.33% 2684 End-of-day quote.11.40%
GILEAD SCIENCES, INC. 0.20% 60.79 Delayed Quote.-6.45%
IMMUNOMEDICS, INC. 0.05% 87.86 Delayed Quote.315.22%
ROCHE HOLDING AG 0.05% 297.4 Delayed Quote.-5.33%
SEAGEN INC. -1.86% 196.92 Delayed Quote.72.54%
share with twitter share with LinkedIn share with facebook
All news about GILEAD SCIENCES, INC.
05:52pStocks mixed; COVID-19 vaccine trials to restart
RE
05:14pGILEAD SCIENCES INC : Completion of Acquisition or Disposition of Assets, Other ..
AQ
04:32pS&P, Nasdaq close higher as stimulus talks in spotlight
RE
04:31pIntel, American Express fall; Mattel, Boston Beer rise
AQ
04:27pASTRAZENECA : Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S...
DJ
02:42pASTRAZENECA : Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S...
DJ
12:28pWHO : Nations mulling Gilead's COVID drug should consider trial flop, too
RE
11:52aWho chief scientist says u.s. regulatory approval for remdesivir as covid-19..
RE
11:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
10:33aS&P 500, Dow edge higher on hopes of progress in stimulus talks
RE
More news
Financials (USD)
Sales 2020 24 029 M - -
Net income 2020 2 246 M - -
Net Debt 2020 3 105 M - -
P/E ratio 2020 37,0x
Yield 2020 4,42%
Capitalization 76 214 M 76 214 M -
EV / Sales 2020 3,30x
EV / Sales 2021 3,24x
Nbr of Employees 11 800
Free-Float 99,6%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 78,08 $
Last Close Price 60,79 $
Spread / Highest target 72,7%
Spread / Average Target 28,4%
Spread / Lowest Target -6,23%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-6.45%76 063
REGENERON PHARMACEUTICALS54.42%60 584
VERTEX PHARMACEUTICALS-3.37%54 719
WUXI APPTEC CO., LTD.58.33%39 347
BEIGENE, LTD.80.38%27 531
GENMAB A/S49.04%22 950